The long-awaited spin-off of Haleon from GSK has arrived, creating new standalone market leader in consumer health, and leaving behind a leaner pharma and vaccines company hoping to reclaim its place as a sector leader.
Consumer Spin-Off Finally Achieved, GSK Will Weigh More M&A
Could Have £12bn To Spend On M&A
GSK is entering a new era, and CEO Emma Walmsley looks likely to use new finances for more targeted M&A.
